z-logo
open-access-imgOpen Access
Cytotoxicity of Cortisone-Resistant Lymphocytes from Mice Treated with a Group A Streptococcus or Freund’s Complete Adjuvant against Tumor Cells
Author(s) -
Shigeru Kigoshi,
Matomo Nishio,
Masafumi Oshita
Publication year - 1985
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.39.225
Subject(s) - cytotoxicity , mesenteric lymph nodes , spleen , adjuvant , streptococcus , lymph node , microbiology and biotechnology , immunology , medicine , biology , in vitro , biochemistry , bacteria , genetics
The cortisone-resistant lymphocytes (CR lymphocytes) of mice treated with a group A streptococcus, Su strain, or Freund's complete adjuvant (FCA) were examined for their cytotoxicity on Ehrlich carcinoma cells and sarcoma-180 cells. Female mice of the ddY strain, 7-8 weeks of age, were injected subcutaneously with streptococci or FCA in emulsion, and they were killed 14 days later. To obtain CR lymphocytes, mice treated with and without agents were injected intraperitoneally with hydrocortisone acetate (125 mg/kg) 2 days before killing. Tumor cells and CR lymphocytes from thymus, spleen or mesenteric lymph node were suspended in Hanks balanced salt solution supplemented with 2% bovine albumin. The cytotoxicity of CR lymphocytes on tumor cells was examined by the Winn test: Tumor growth was observed in mice inoculated s.c. with the mixture of tumor cells (T) and CR lymphocytes (L) at a T/L ratio of 1/10 (10(6) tumor cells/mouse). The mesenteric and thymic CR lymphocytes of mice treated with streptococci or FCA were more effective than the corresponding lymphocytes of untreated mice in suppressing the tumor growth in animals given the cell mixture. This suggests that the treatment of mice with streptococci or FCA results in an enhancement in the cytotoxicity of mesenteric and thymic CR lymphocytes against the tumor cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here